You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 5,310,727

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,310,727

Title:	Pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
Abstract:	A freeze-dried pharmaceutical composition for parenteral administration which includes a therapeutically effective amount of a calcitonin, as the active ingredient, and human albumin. The injectable solution which is obtained by dissolving the freeze-dried composition in a physiologically acceptable solvent is also described.
Inventor(s):	Lattanzi; Filippo (Siena, IT), Vanni; Riccardo (Siena, IT)
Assignee:	Scalvo S.p.A. (Siena, IT)
Application Number:	07/620,399
Patent Claims:	1. A lyophilized pharmaceutical composition comprising calcitonin and from 0.005 to 2.5 mg of human albumin per IU of calcitonin. 2. The composition of claim 1 wherein the amount of human albumin is between 0.05 and 2 mg per IU of calcitonin. 3. The composition of claim 2 wherein the amount of human albumin is between 0.1 and 1.2 mg per IU of calcitonin. 4. The composition of claim 1 wherein calcitonin is salmon calcitonin or eel calcitonin. 5. The composition of claim 4 wherein calcitonin is eel calcitonin. 6. The composition of claim 1 which further comprises a pharmaceutically acceptable acid, acid salt or acid buffer in a concentration sufficient to impart a pH of from 3.5 and 5.5 to the composition. 7. The composition of claim 6 wherein the concentration of said acid, acid salt or acid buffer is sufficient to impart a pH of from 4.0 and 5.0 to the composition. 8. The composition of claim 7 wherein the concentration of said acid, acid salt or acid buffer is sufficient to impart a pH of from 4.4 and 4.8 to the composition. 9. The composition of claim 6 wherein said acid salt is monobasic sodium phosphate. 10. The composition of claim 1 containing from 1 to 250 IU of calcitonin. 11. A single-dose administration unit consisting of the composition of claim 10 and from 1 to 5 ml of a physiologically acceptable solvent. 12. The single-dose administration unit of claim 11 wherein the amount of calcitonin is between 10 and 200 IU. 13. The single-dose administration unit of claim 11 wherein the physiologically acceptable solvent is sterile water. 14. A lyophilized pharmaceutical composition which comprises eel calcitonin and from 0.1 to 1.2 mg of human albumin.

Details for Patent 5,310,727

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2011-05-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.